SUV39H1

Histone-lysine N-methyltransferase SUV39H1 · O43463 · SUV39H1 on Sugi Atlas →

1,917 patent compounds predicted against SUV39H1, 1,342 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Chetomin (SCHEMBL1098248)	1.00	4/20
Chetomin (SCHEMBL12018744)	1.00	4/20
Chaetocin (SCHEMBL13662582)	1.00	4/20
Chaetocin (SCHEMBL13662584)	1.00	4/20
Chaetocin (SCHEMBL14021817)	1.00	4/20
Chetomin (SCHEMBL14021824)	1.00	4/20
Verticillin B (SCHEMBL5894069)	0.57	4/20
SCHEMBL3399921	0.56	4/20
SCHEMBL13821502	0.55	4/20
Gliotoxin (SCHEMBL54420)	1.00	3/20
Gliotoxin (SCHEMBL4294337)	1.00	3/20
Gliotoxin (SCHEMBL9667270)	1.00	3/20
Gliotoxin (SCHEMBL12018743)	1.00	3/20
Gliotoxin (SCHEMBL12149513)	1.00	3/20
Gliotoxin (SCHEMBL12618354)	1.00	3/20
Gliotoxin (SCHEMBL13341245)	1.00	3/20
Gliotoxin (SCHEMBL14514067)	1.00	3/20
Gliotoxin (SCHEMBL14579856)	1.00	3/20
Gliotoxin (SCHEMBL14986985)	1.00	3/20
Gliotoxin (SCHEMBL14332623)	0.71	3/20

Clinical trials — most relevant to SUV39H1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG	PHASE1/PHASE2	RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS	PHASE1/PHASE2	WITHDRAWN
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer	PHASE1/PHASE2	RECRUITING
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)	PHASE1/PHASE2	COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Tazemetostat and Palbociclib With CPX-351for R/R AML	PHASE1	RECRUITING
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid	EARLY_PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Mechanisms of Immune Deficiency	nan	UNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SUV39H1 binder may also engage these)

Protein	Name	Similarity
Q5RB81	—	1.000	Q5RB81 →
Q2NL30	—	1.000	Q2NL30 →
O54864	—	0.998	O54864 →
Q32PH7	—	0.994	Q32PH7 →
Q28CQ7	—	0.993	Q28CQ7 →
Q4R3E0	—	0.993	Q4R3E0 →
Q6DGD3	—	0.992	Q6DGD3 →
SUV39H2	Histone-lysine N-methyltransferase SUV39H2	0.992	landscape →
Q6NRE8	—	0.991	Q6NRE8 →
Q5F3W5	—	0.988	Q5F3W5 →
Q9EQQ0	—	0.987	Q9EQQ0 →
Q945S8	—	0.985	Q945S8 →
Q949T8	—	0.983	Q949T8 →
P45975	—	0.981	P45975 →
Q8GZB6	—	0.981	Q8GZB6 →
Q8W595	—	0.981	Q8W595 →
Q80UJ9	—	0.980	Q80UJ9 →
Q294B9	—	0.980	Q294B9 →
O60016	—	0.978	O60016 →
Q09265	—	0.978	Q09265 →
Q9C5P1	—	0.978	Q9C5P1 →
O65312	—	0.977	O65312 →
Q9M1X9	—	0.976	Q9M1X9 →
Q5I0M0	—	0.974	Q5I0M0 →
O22781	—	0.974	O22781 →
Q6K431	—	0.974	Q6K431 →
KDM5B	Lysine-specific demethylase 5B	0.974	landscape →
Q757Y8	—	0.974	Q757Y8 →
A8WTV9	—	0.974	A8WTV9 →
B3M0F3	—	0.974	B3M0F3 →